DIRS.INFO The most relevant business & tech news

☆ Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
▼ + stars: | 2024-07-24 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval. Without enough of that protein, the blood cannot clot properly, increasing the risk of spontaneous bleeding and severe bleeding after surgery. Pfizer said its one-time treatment significantly cut the number of annual bleeding episodes in patients with moderately severe to severe hemophilia A after 15 months. If approved, Pfizer's therapy will compete with BioMarin Pharmaceutical 's one-time treatment Roctavian. BioMarin is reportedly considering whether to divest its hemophilia A therapy, which costs $2.9 million.

Persons: Andrew Leavitt, Pfizer Organizations: Pfizer, Sangamo Therapeutics, BioMarin Locations: U.S

☆ Alphabet earnings and 3 more things we're watching in the stock market next week
▼ + stars: | 2024-07-20 | by ( Zev Fima | ) www.cnbc.com time to read: +12 min

But in general, this is the kind of development we've hoped to see ever since Starbucks' massive earnings miss April 30. We'll take the nearly 7% pop in shares Friday and hope it's only the beginning of recovery for the beaten-up stock. Fed's fave inflation measure : The personal spending and income report will be the most closely watched economic report next week. Earnings : As the second-quarter earnings season picks up pace, we'll hear from five Club holdings next week including Google parent Alphabet . Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio.

Persons: Russell, Donald Trump, — Trump, Jim Cramer, Trump, Donald Trump's, Taiwan's TSMC, Joe Biden's, Biden, Biden's, he's, Elliott, we've, We'll, it's, we'll, Sartorius, Ford, Jim Farley, We're, Honeywell management's, —, Zions, BOK, Brown, BRO, Lockheed Martin, Philip Morris, Clark, Lamb, Edwards Lifesciences, DOV, Dr Pepper, CARR, Baker Hughes, Booz Allen Hamilton, Jim Cramer's, Jim Organizations: Federal Reserve, Nasdaq, Dow, Republican National Convention, GOP, Bloomberg Businessweek, Trump, Elliott Management, Starbucks, Street Journal, Technology, General Motors, Honeywell, Dover, Products Company, Verizon, Truist, SAP, Semiconductors, Crown Holdings, Cadence Design Systems, Medpace Holdings, AGNC Investment, Logitech International S.A, KKR Real Estate Finance Trust, Berkley Corp, Spotify Technology S.A, United Parcel Service, GE Aerospace, GE, Cola Company, Lockheed, Comcast, Polaris Industries, Philip Morris International, Company, HCA Healthcare, Moody's Corporation, Enphase Energy, Texas Instruments Incorporated, Chubb Corporation, Seagate Technology plc, Maine, Packaging Corporation of America, Weatherford International plc, Canadian National Railway Company, FTAI Aviation Ltd, Mattel, Vertiv Holdings Co, Lamb Weston Holdings, NextEra Energy, Tenet Healthcare, Fisher, GE Vernova, Boston Scientific Corporation, General Dynamics, Lennox International, Software Technologies, CME Group, Fortive Corporation, Co, Roper Technologies, Teck Resources Limited, Blackstone Mortgage Trust, Economico Mexicano S.A, Dominion Freight, Otis Worldwide Corporation, OTIS, Ford Motor Company, Grill, Business Machines, IBM, Viking Therapeutics, Las Vegas Sands Corp, Newmont, Whirlpool, Globe, WM, O'Reilly Automotive, Annaly Capital Management, Honeywell International, American Airlines Group, Hasbro, Southwest Airlines Co, New York Community Bancorp, RTX Corporation, AstraZeneca, Carrier Global Corporation, Integer Holdings Corporation, Valero Energy, Texas, Juniper Networks, Boston Beer Company, Physicians Realty Trust, Allison Transmission Holdings, Corp, Columbia Banking, Digital Realty Trust, Edison International, Myers Squibb, Charter Communications, 3M Company, Booz, Centene Corporation, AON, Barnes, Colgate, Palmolive, Jim Cramer's Charitable, CNBC, U.S Locations: U.S, Taiwan, FactSet, China, Dover, Cleveland, Alexandria, ZION, W.R, Freeport, Kimberly, Cal, Teck, Las, ORLY, New, Banc, Bristol, Milwaukee , Wisconsin

☆ Sealed bottles of tattoo and permanent makeup ink test positive for millions of bacteria, FDA says
▼ + stars: | 2024-07-18 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +8 min

CNN —Sealed bottles of tattoo and permanent makeup ink, including some marked as sterile, contained millions of potentially dangerous bacteria, according to new research by the US Food and Drug Administration. Earlier studies have found high levels of bacterial contamination within sealed and sterile bottles of ink. Unfortunately, the study’s findings were not surprising, said John Swierk, an assistant professor of chemistry at Binghamton University, State University of New York, who has studied tattoo ink contamination. For example, using the same gloves to touch a client and the ink bottle is a hazard that can lead to tattoo ink contamination. “Tattoo inks are in the process of being regulated due to the Modernization of Cosmetics Regulation Act (of 2022) but much of that law dealing with tattoo inks has yet to be implemented,” Swierk said.

Persons: ”, Peter, Kim, Linda Katz, ” Katz, Katz, John Swierk, Swierk, Selina Medina, ” Medina, Robert Schooley, “, ’ ”, Schooley, Medina, miodrag ignjatovic, ” Swierk Organizations: CNN, US Food and Drug Administration, National, for Toxicological Research, Cosmetics, US Centers for Disease Control, Binghamton University, State University of New, Alliance, Professional, Manufacturers, FDA, CFU, University of California, Center, Therapeutics, Artists Locations: Jefferson , Arkansas, State University of New York, United States, San Diego, Medina

☆ Cramer's Lightning Round: Don't sell Match Group
▼ + stars: | 2024-07-16 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon Fortinet's year-to-date stock performance. Stock Chart Icon Stock chart icon Sarepta Therapeutics' year-to-date stock performance. Stock Chart Icon Stock chart icon Toast's year-to-date stock performance. Stock Chart Icon Stock chart icon Teva Pharmaceutical's year-to-date stock performance. Stock Chart Icon Stock chart icon Viking Holdings' year-to-date stock performance.

Persons: Palo, Linde's, you've, You've, there's, Teva, Eli Lilly, Jim Cramer's Organizations: Charitable Trust, Products, Air Products, Therapeutics, Sarepta Therapeutics, BJ's Wholesale, Costco, ., Teva, Viking Holdings, Royal Locations: Palo Alto, Linde, Royal Caribbean

☆ Small caps are surging. Oppenheimer found a 'broadening' bull market favors future returns
▼ + stars: | 2024-07-15 | by ( Samantha Subin | ) www.cnbc.com time to read: +1 min

Oppenheimer views last week's rally in small-cap stocks as a potential catalyst for the wider market and its future returns. "The point is that last week's small-cap breakout marks a re-broadening of the bull that should carry bullish implications for all capitalizations." .RUT YTD mountain Performance in 2024 The comments from Wald came on the heels of last week's 6% surge in the Russell 2000 index of small caps. The iShares Russell 2000 ETF added as much as another 1.6% early in Monday's session. "In our view, this cycle's 'as good as it gets moment' has not yet been reached," Wald said.

Persons: Oppenheimer, Ari Wald, Wald, Russell Organizations: Federal Reserve, Viking Therapeutics, Zeta Global

☆ The best small- and midcap stocks to buy this summer, according to Oppenheimer
▼ + stars: | 2024-07-10 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

With the second half of the year underway, Oppenheimer is highlighting what it calls its top small- and midcap seasonal standout investment ideas. On the basis of price charts alone, Oppenheimer tapped midcap growth stocks as its top rotation idea from a technical perspective. Oppenheimer has a $20 price target on Zeta, implying 18% upside from Tuesday's close. In a note last month, RBC Capital Markets also rated Zeta outperform with a price target of $20. In this area, Oppenheimer likes Viking Therapeutics , reiterating the stock as one of its best ideas.

Persons: Oppenheimer, Russell, Brian Schwartz, Zeta, Novo Nordisk's Wegovy, Eli Lilly's Zepbound, Jay Olson, Freshpet Organizations: Oppenheimer, Zeta Global Holdings, Zeta, RBC Capital Markets, Novo Nordisk's, Viking Therapeutics, Therapeutics Locations: Zeta, Novo

☆ Investors want proof AI will aid drug discovery. Evidence may come in the second half
▼ + stars: | 2024-07-06 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +10 min

Analysts who have been following companies on the cutting edge of using generative AI for drug discovery say it is still very early days. But these endorsements haven't lifted Recursion shares out of a slump. RXRX 1Y mountain Recursion shares over the past year. The drug company will be a beta user of Recursion's LOWE (Large Language Model-Orchestrated Workflow Engine) and the pair are also partnering on oncology research. SDGR 1Y mountain Schrodinger shares over the past year.

Persons: Scott Schoenhaus, Chris Gibson, Jensen Huang, Leerink, Mani Foroohar, Foroohar, Recursion's, KeyBanc's Schoenhaus, Needham, Gil Blum, it's, Recursion's LOWE, Blum, Eli Lilly, AbCellera, KeyBanc's, Schoenhaus, FactSet, Allison Bratzel, Piper Sandler, Goldman Sachs, Salveen Richter, Peter Lawson, Lawson, Japan's Takeda, Schrodinger, Leerink's Foroohar Organizations: Analysts, Capital, Nvidia, ARK Investment Management, REC, CCM, Union, Bayer, Therapeutics, Dynamo, RLY, Barclays, Japan's Locations: U.S, biopharma, Biohive

☆ Here are Tuesday's biggest analyst calls: Amazon, Nvidia, Tesla, Uber, Disney, PayPal, Spotify, Chevron, Netflix & more
▼ + stars: | 2024-07-02 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

"We initiate coverage of Waystar ( WAY) with a Buy rating and 12-month price target of $32." Bank of America reiterates Nvidia as buy Bank of America said Nvidia was the "most-owned" stock in semis among fund managers. Bank of America reiterates Disney as buy Bank of America said it's sticking with its buy rating on the stock. " Argus reiterates Netflix as buy Argus said it's sticking with its buy rating on the stock. "We are maintaining our BUY rating on Focus List selection Netflix I nc.

Persons: Mizuho, Goldman Sachs, Goldman, it's, Nvidia, NVDA, AVGO, Piper Sandler downgrades CrowdStrike, Piper, Raymond James, Piper Sandler, Jefferies, RAPP, Stifel, MAUs, Wells, Roth, WULF, VIK, Horton, Guggenheim, Tesla, Kitty Organizations: Mizuho, Amazon, " Bank of America, Nvidia, Bank of America, AMD, Comerica, UBS, TEAM, Rapport Therapeutics, Life360 Inc, Spotify, Hess Corp, IT Services, Barclays, Viking Holdings, Citi, Disney, DIS, NBA, Susquehanna, PayPal, of America, Deutsche Bank, Uber, Deutsche, Netflix, Argus Locations: CrowdStrike, Chevron

☆ Here are Thursday's biggest analyst calls: Nvidia, Apple, Broadcom, Micron, Goldman Sachs, Carvana, Arista & more
▼ + stars: | 2024-06-27 | by ( Michael Bloom | ) www.cnbc.com time to read: +6 min

Here are Thursday's biggest calls on Wall Street: Goldman Sachs reiterates Micron as buy Goldman said investors should buy the dip in the stock following earnings on Wednesday. Jefferies reiterates Nvidia, Marvell and Broadcom as buy Jefferies said it's sticking with its buy rating on all three companies. " Morgan Stanley initiates Viking Therapeutics as overweight Morgan Stanley said the biotech company has "best-in-class potential." Morgan Stanley adds Goldman Sachs to the financials finest list Morgan Stanley added the investment banking giant to its top financials ideas list. Morgan Stanley reiterates Coca-Cola as overweight Morgan Stanley said it's sticking with its overweight rating on the beverage giant.

Persons: Goldman Sachs, Goldman, Bernstein, Apple, Mizuho, KBW, it's, Jefferies, AVGO, KeyBanc, Texas Consolidator, TD Cowen, Grindr, GRND, Morgan Stanley, JPM, Oppenheimer, Kyndryl, CVNA, Truist Organizations: Micron, Apple, Bank of America, Petrobras, of America, Mizuho, Holdings, Grab Holdings, New York Mellon, Deutsche Bank, Emerson Electric Deutsche Bank, Nvidia, Marvell, Broadcom, Energy, Crescent Energy Co, Citi, Arista Networks, Arista, Viking Therapeutics, Macquarie, TPG, Markets, JPMorgan, Bancorp, UBS, Disney, Cable Locations: MU, Brazil, Texas, North America, CA

☆ Here are Oppenheimer's top stock picks heading into July
▼ + stars: | 2024-06-25 | by ( Sean Conlon | ) www.cnbc.com time to read: +3 min

Oppenheimer unveiled its top stock ideas heading into a new trading month, all of which are seen outperforming over the next 12 months in the market's current conditions. While Oppenheimer has a price target at $75 for the stock, implying about 8.9% upside from Monday's close, JPMorgan is even more bullish. With a $116 price target, Oppenheimer sees similar gains still ahead. Oppenheimer has its price target set at $2,000, which implies a 25.6% increase from Monday's close. On Monday, it hiked Broadcom's price target to $2,150 and said the buy-rated stock is a top pick.

Persons: Oppenheimer, Jefferies, Rick Schafer, Goldman Sachs Organizations: United Therapeutics, Walmart, JPMorgan, Broadcom, Bank of America, Dick's Sporting Goods Locations: Centene, United

☆ Cramer's Lightning Round: 'I would not abandon' Cava
▼ + stars: | 2024-06-24 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Viking Therapeutics' year-to-date stock performance. Stock Chart Icon Stock chart icon Cava's year-to-date stock performance. Stock Chart Icon Stock chart icon Rubrik's year-to-date stock performance. Stock Chart Icon Stock chart icon Forward Air's year-to-date stock performance. Stock Chart Icon Stock chart icon Bristol Myers Squibb's year-to-date stock performance.

Persons: Lilly, Bristol Myers, Meyers, Jim Cramer's Organizations: Therapeutics, Viking Therapeutics, Forward, Bristol Myers Squibb

☆ CNBC Daily Open: Dow posts best week since May, Tesla staff down by 14%
▼ + stars: | 2024-06-24 | by ( Abid Ali | ) www.cnbc.com time to read: +3 min

This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. The tech-centric Nasdaq Composite remained flat, while the Dow Jones Industrial Average had its best week since May, rising 1.45%. The yield on the 10-year Treasury ticked higher and U.S. oil prices rose 2.9% for the week. [PRO] Comeback stocksThe S&P 500 has soared to record levels, fueled by the AI boom, but not all stocks are riding the wave.

Persons: JPMorgan Chase, Goldman Sachs, Tesla, Elon Musk, Musk, Tim Lugo, William Blair's Organizations: CNBC, Nvidia, Microsoft, Apple, Nasdaq, Dow Jones, Citigroup, JPMorgan, Bank of America, Apple Intelligence, Union, Therapeutics, FDA, Organization for Rare Disorders, Nike, Starbucks Locations: U.S

☆ Stocks making the biggest moves midday: ResMed, Affirm, Nvidia, Anheuser-Busch and more
▼ + stars: | 2024-06-24 | by ( Michelle Fox | ) www.cnbc.com time to read: +4 min

Affirm — The buy now, pay later stock popped 10% after Goldman Sachs assumed coverage of the name at a buy rating. Roth MKM upgraded Cinemark to a buy from a neutral rating, saying that headwinds should soon shift to "very attractive tailwinds." Anheuser-Busch InBev — The brewing company's shares rose around 3% after UBS upgraded the stock to buy from neutral. Carrier Global — The heating and ventilation stock rose 3% on the heels of a Citi upgrade to buy from neutral. Energy stocks – A slate of energy names rose as crude oil futures jumped to start the last week of June.

Persons: Eli Lilly, tirzepatide, Eli Lilly's, ATTR, Goldman Sachs, Will Nance, Roth MKM, headwinds, Morgan Stanley, Cowen, Ferrari, Brent, SLB, Baker Hughes, — CNBC's Lisa Han, Jesse Pound, Alex Harring, Sean Conlon, Samantha Subin Organizations: Systems, Food and Drug Administration, Coyote Logistics, UPS, Alnylam Pharmaceuticals, Nvidia, Microsoft, Anheuser, Busch InBev, UBS, Busch, IBM, Ryder, Carrier, Citi, Ferrari —, Energy, West Texas Intermediate, APA Locations: U.S

☆ Stocks making the biggest moves premarket: Gilead Sciences, Sarepta Therapeutics, Nike and more
▼ + stars: | 2024-06-21 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

The decline comes after the AI chipmaker on Tuesday briefly topped Microsoft as the most valuable public company. Nike — The athletic clothing maker moved 1% higher following an upgrade at Oppenheimer to outperform from market perform. Asana — Shares popped more than 3% after the software firm announced a $150 million share buyback plan. Gilead Sciences — The pharmaceutical stock rose more than 2.6%, building on a rally of 8.5% from the previous session. Delta Air Lines — The stock rose 0.7% following news Thursday that the airliner announced a quarterly dividend of 15 cents a share, a 50% increase from previous levels.

Persons: Oppenheimer, Gilead, LendingTree, Bernstein, Toni Sacconaghi, — CNBC's Brian Evans, Michelle Fox, Jesse Pound, Sarah Min Organizations: Nvidia, Microsoft, Sarepta Therapeutics, U.S . Food, Drug Administration, Nike, Gilead Sciences, Bloomberg, Apple —, Air Lines Locations: U.S, Gilead

☆ Stocks making the biggest moves midday: Sarepta Therapeutics, Hertz Global, Asana and more
▼ + stars: | 2024-06-21 | by ( Sean Conlon | ) www.cnbc.com time to read: +2 min

Hertz Global — Shares rose more than 10% after the car rental giant upsized a bond offering to $1 billion . Asana — The stock popped 10.5% after the software firm announced a share buyback plan that would cost $150 million. Nvidia — The chipmaker dropped another 1% following a 3.5% decline in the previous session. Gilead Sciences — Shares of the pharmaceutical company popped around 2%, adding to an 8.5% rally from the previous session. Palo Alto Networks — Shares rose 2.4% after D.A.

Persons: Gilead, LendingTree, Davidson, D.A, Boyd Gaming, Boyd, —, Alex Harring, Yun Li, Lisa Kailai Han, Hakyung Kim, Michelle Fox Organizations: Therapeutics, U.S . Food, Drug Administration, FDA, Hertz, Nvidia, Gilead Sciences, Bloomberg, Palo Alto, D.A, Penn Entertainment, Boyd, Reuters, Boeing Locations: U.S, Gilead, Palo, cybersecurity, Thursday's

☆ How A.I. Is Revolutionizing Drug Development
▼ + stars: | 2024-06-17 | by ( Steve Lohr | Spencer Lowell | ) www.nytimes.com time to read: 1 min

The laboratory at Terray Therapeutics is a symphony of miniaturized automation. Robots whir, shuttling tiny tubes of fluids to their stations. Scientists in blue coats, sterile gloves and protective glasses monitor the machines. Every interaction is recorded, millions and millions each day, generating 50 terabytes of raw data daily — the equivalent of more than 12,000 movies. The lab, about two-thirds the size of a football field, is a data factory for artificial-intelligence-assisted drug discovery and development in Monrovia, Calif. It’s part of a wave of young companies and start-ups trying to harness A.I.

Organizations: Terray Therapeutics Locations: Monrovia, Calif

☆ Structure Therapeutics CEO on GLP drugs
▼ + stars: | 2024-06-11 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailStructure Therapeutics CEO on GLP drugsRay Stevens, Structure Therapeutics CEO, joins 'Fast Money' to discuss the weight loss drug boom and the company's recent data finidngs in its own drug.

Persons: Ray Stevens Organizations: Structure Therapeutics

☆ Alphabet's new CFO was in the middle of the GLP-1 boom. Now she's onto generative AI
▼ + stars: | 2024-06-06 | by ( Jennifer Elias | ) www.cnbc.com time to read: +10 min

Alphabet announced on Wednesday that Eli Lilly Chief Financial Officer Anat Ashkenazi will be its new CFO after an almost year-long search. Shares of Eli Lilly have soared 90% in the past year and are trading at a record. When she joined Eli Lilly in 2001, she came in through the company's new venture capital division, which was co-founded by her then-spouse Ron Laufer. Fastest growth in decadesFounded in 1876, Eli Lilly has long been one of the major U.S. pharmaceutical companies. But the last couple years have marked a period of historic growth for Eli Lilly due to the exploding popularity of GLP-1s.

Persons: Anat Ashkenazi, Eli Lilly Eli Lilly Alphabet's, Ruth Porat, Eli Lilly, Ashkenazi, it's, Eli Lilly's, David Ricks, Morgan Stanley, Sundar Pichai, Hollie Adams, Ron Laufer, John Smiley, Eli, It's, Trump, Eli Lilly's Covid, we're, Askhenazi, OpenAI's, Larry Page, Sergey Brin, CNBC's Eric Rosenbaum, Toby Lyles Organizations: San, San Francisco Bay Area, Google, Economic, Bloomberg, Getty, CNBC, Tel Aviv University, Hebrew University, U.S . Food, Drug, U.S . Department of Justice, FDA, Reuters, Employees, NBC Locations: U.S, Indiana, San Francisco Bay, Davos, Switzerland, Israel, biopharma, North Carolina, Germany, New Jersey

☆ Stocks making the biggest moves before the bell: Robinhood, Nvidia, Lululemon, Five Below and more
▼ + stars: | 2024-06-06 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

Five Below told investors to expect between $830 million and $850 million, while analysts polled by LSEG forecasted $883 million. Sprinklr — The business technology stock dove 21.1% in the wake of weak guidance for the current quarter and full year. StoneCo — The financial technology stock rose 2.6% following an upgrade to overweight from neutral by JPMorgan . Ultragenyx Pharmaceutical — The biopharma stock added nearly 4% following an upgrade to buy from neutral at Goldman Sachs. Shopify — The e-commerce technology stock slipped 1.6% on the back of a MoffettNathanson downgrade to neutral from buy.

Persons: Goldman Sachs, Smartsheet, LSEG, Sprinklr, Mizuho, there's, StoneCo, CH Robinson, Goldman, ISI's, Shopify, Guggenheim, —, Jesse Pound, Michelle Fox, Lisa Kailai Han Organizations: Nvidia, LSEG, Revenue, Mizuho, JPMorgan, Ultragenyx Pharmaceutical, Goldman, eBay, Citi, UBS, BMO Capital, BMO, Viridian Therapeutics, ISI, Energy Locations: Americas

☆ PTSD Treatments Are Falling Short for Many Patients
▼ + stars: | 2024-06-04 | by ( Dani Blum | ) www.nytimes.com time to read: +1 min

They withdraw — often reluctant to talk about what they’ve experienced and unable to trust others or themselves. The treatments for PTSD — including several forms of psychotherapy and medication — are effective for many patients, but they don’t work for everyone. Sometimes, they can be so distressing that patients stop the treatment before it’s complete. On Friday the Food and Drug Administration declined to approve what would have been the first new treatment for PTSD in decades, a therapy that combined the psychoactive drug MDMA with talk therapy. approve the treatment, citing concerns about safety and issues in clinical trials.

Persons: —, it’s Organizations: and Drug Administration, Lykos Therapeutics

☆ F.D.A. Panel Weighs MDMA Therapy and Its Risks
▼ + stars: | 2024-06-04 | by ( Andrew Jacobs | ) www.nytimes.com time to read: +1 min

The Food and Drug Administration is weighing whether to approve the use of MDMA, also known as Ecstasy, for treatment of post-traumatic stress disorder. An independent advisory panel of experts will review studies on Tuesday and is expected to vote on whether the treatment would be effective and whether its benefits outweigh the risks. The panel will hear from Lykos Therapeutics, which has submitted evidence from clinical trials in an effort to obtain agency approval to sell the drug legally to treat people with a combination of MDMA and talk therapy. Methylenedioxymethamphetamine (MDMA) is a synthetic psychoactive drug first developed by Merck in 1912. After being resynthesized in the mid-1970s by Alexander Shulgin, a psychedelic chemist in the Bay Area, MDMA gained popularity among therapists.

Persons: Alexander Shulgin Organizations: Drug Administration, Lykos Therapeutics, Merck Locations: Bay

☆ F.D.A. Panel Rejects MDMA-Aided Therapy for PTSD
▼ + stars: | 2024-06-04 | by ( Andrew Jacobs | ) www.nytimes.com time to read: +1 min

An independent advisory panel of the Food and Drug Administration rejected the use of MDMA-assisted therapy for post-traumatic stress disorder on Tuesday, highlighting the unparalleled regulatory challenges of a novel therapy using the drug commonly known as Ecstasy. Before the vote, members of the panel raised concerns about the designs of the two studies submitted by the drug’s sponsor, Lykos Therapeutics. The panel voted 9-2 on whether the MDMA-assisted therapy was effective, and voted 10-1 on whether the proposed treatment’s benefits outweighed its risks. Other panelists expressed concerns over the drug’s potential cardiovascular effects, and possible bias among the therapists and facilitators who guided the sessions and may have positively influenced patient outcomes. A case of misconduct involving a patient and therapist in the study also weighed on some panelists’ minds.

Organizations: Food and Drug Administration, Lykos Therapeutics

☆ Moderna, Merck say vaccine improved survival in patients with deadly skin cancer
▼ + stars: | 2024-06-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Moderna and Merck released more positive three-year data Monday on their experimental vaccine, given to patients with the most deadly form of skin cancer in combination with the therapy Keytruda. The vaccine together with Merck's Keytruda improved survival and showed long-lasting efficacy in a midstage study in patients with a deadly form of skin cancer. Melanoma is responsible for the large majority of skin cancer deaths, according to the American Cancer Society. Moderna is also conducting another phase three trial of the vaccine in patients with a type of lung cancer. This year, Merck and Moderna started a two-part mid- to late-stage trial on the vaccine and Keytruda in patients at an advanced stage of a common skin cancer.

Persons: Merck's, Kyle Holen, Keytruda, Stephane Bancel, Bancel Organizations: Moderna, Merck, American Society of Clinical Oncology, CNBC, U.S . Food, Drug Administration, FDA, American Cancer Society Locations: Chicago, U.S, Moderna

☆ Structure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared Holz
▼ + stars: | 2024-06-03 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailStructure Therapeutics is a 'no-brainer takeout' target, says Mizuho's Jared HolzJared Holz, Mizuho, joins 'Fast Money' to talk Structure Therapeutics soaring on its GLP-1 data and M&A targets in the obesity drug space.

Persons: Jared Holz Jared Holz Organizations: Therapeutics Locations: Mizuho

☆ Stocks making the biggest moves midday: GameStop, Paramount, Spotify, Krispy Kreme and more
▼ + stars: | 2024-06-03 | by ( Alex Harring | ) www.cnbc.com time to read: +5 min

Waste Management , Stericycle — Waste Management is buying Stericycle for $7.2 billion , the companies announced on Monday. Stericycle shares jumped nearly 15%, while Waste Management slid 4%. Spotify — The music streaming company climbed 4% following its announcement of premium subscription price increases in the U.S. in July. Lattice Semiconductor , Coherent — Lattice shares dove 11% after CEO Jim Anderson left to take the helm at Coherent, whose stock price jumped 17%. Krispy Kreme — Shares of the company rose 2% after it was upgraded to overweight at JPMorgan.

Persons: Keith Gill, Gill, Stericycle, CNBC's David Faber, Skydance, Shari Redstone, Jim Anderson, Esam, Dickinson, Edwards, Narendra Modi, Claudia Sheinbaum, Cava, Blackwell, Krispy Kreme, Masimo, Piper, Piper Sandler, Goldman Sachs, Goldman, — CNBC's Sean Colon, Yun Li, Pia Singh, Michelle Fox, Christina Cheddar, Berk Organizations: GameStop, DeepF, AMC, New York Stock Exchange, Waste Management, Spotify, GSK, Court, Paramount Global, Lattice Semiconductor, Company, Bloomberg News, JPMorgan, Nvidia, AMD, Bank of America, Therapeutics, Autodesk Locations: U.S, Swedish, Delaware, Becton, India, Mexico

Search resuls for: "THERAPEUTICS"

25 mentions found